API Purification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

API Purification
Pharmaceutical Technology Europe speaks to Peter Koklitis, a technical filtration specialist at 3M's purification division, about the latest trends, techniques and technologies in API purification.


Pharmaceutical Technology Europe
Volume 23, Issue 9

What are the currently preferred methods of purification for synthetic APIs and API bioprocessing?


Peter Koklitis
In processes that use a series of chemical reaction steps to synthesise the API, the removal of reaction by-products, including colour bodies and metals, is critical to produce high quality pharmaceuticals. The preferred methods for removing residual metal catalysts are distillation, crystallisation and precipitation. A distillation collects the pure API as a distillate, leaving the non-volatile compounds in the residue, while crystallisation and precipitation steps both generate solid material that can be physically removed by selecting a filtration step. In addition, both chromatography and activated carbon powder treatments are used to exploit charge and adsorptive technologies for impurity removal.

In bioprocessing, whereby APIs are isolated and purified following clarification steps of mammalian or bacterial cell harvests, a combination of affinity and ion-exchange chromatography are used in conjunction with filtration steps. Protein A coupled to an agarose matrix is now widely used as an effective affinity column for the purification of monoclonal antibodies, while anion-exchange chromatography is used for host cell impurity removal.

What are the latest significant innovations in API purification?

In synthetic API manufacture, the use of metal catalysts, such as Palladium, has increased from using convergent reaction processes to prepare chemical fragments in parallel, which are coupled together to form the API. In these processes, there is a choice to use either homogeneous (non-immobilised and dissolved) or heterogeneous (immobilised) metal catalyst systems. For example, many reactions use Palladium bound to carbon (Pd/C), as these offer high surface area supports which are relatively easily and inexpensively prepared.

Several companies have specialised in providing heterogeneous catalysts, such as using highly cross-linked microporous matrices, which retain catalytic activity and enable the metal to be reclaimed and reused, but there are other examples where specific functional groups on a polymer backbone or alumina have been used to attach the metal catalyst. Heterogeneous metal catalysts bound to supports are easily separated by filtration after the reaction (e.g., Suzuki, Heck and Sonogashu), although leaching of the metal may occur. The removal of metal residuals has resulted in the need to develop rapid screening devices to identify suitable adsorbents. There are a wide range of adsorbents to consider for metal removal, e.g. activated carbon, functionalised polymer resins, silica, diatomaceous earth, alumina and clay—the choice is dependent on the degree of selectively required and cost of ownership.

In API bioprocess applications, there have been several recent innovations to provide single-use systems that enable modularisation. For example, large-depth filter systems used in cell harvest clarification are now being considered as single use because of developments in encapsulation technology. The desire to engineer modular processing units also exists for API synthetic processes; a modular platform approach provides faster and easier scale up for new processes, with clear visibility of capital and variable costs. These innovations also provide operational flexibility, while reducing equipment-cleaning issues at the same time.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology Europe,
Click here